Start
•
Completion

Ketamine for the treatment of depression with anorexia nervosa

RecruitingRegisteredISRCTN

This randomised, double-blind, placebo-controlled Phase II trial (n=60) will study the feasibility, safety, and acceptability of oral ketamine (60–180 mg, administered twice weekly) as a treatment for adults with long-standing anorexia nervosa and comorbid treatment-resistant depression.

Details

Randomised, single-centre, double-dummy, quadruple-blind feasibility trial (EDEN) comparing oral KET-IR (60–180 mg) versus placebo, dosed twice weekly for four weeks (eight supervised in-person dosing sessions).

Primary outcomes focus on feasibility metrics (recruitment, retention, adherence); exploratory clinical measures include MADRS for depression, EDE-Q for eating disorder psychopathology, quality of life (EQ-5D-5L), and safety/tolerability.

Topics:Depressive Disorders

Registry

Registry linkISRCTN26462355